Patients with non-small cell lung cancer, especially adenocarcinomas, harbour at least one
oncogenic driver mutation that can potentially be a target for therapy. Treatments of these …

The advent of molecular profiling and the generalization of next generation sequencing in
oncology has enabled the identification of patients who could benefit from targeted agents …

The ROS1-positive iHGGs are an exceptionally rare tumor subtype with a relatively poor
prognosis. 1 The most typical ROS1 fusion partner for such tumors is GOPC. 2 Here we …

Targeted therapy has become one of the standards of care for advanced lung cancer. More
than 10 genetic aberrations have been discovered that are actionable and several tyrosine …

Lung cancer is a major cause of death worldwide, being often detected at a later stage due
to the non-appearance of early symptoms. Therefore, specificity of the treatment is of utmost …

Introduction The study of resistance-causing mutations in oncogene-driven tumors is
fundamental to guide clinical decisions. Several point mutations affecting the ROS1 kinase …

Simple Summary Crizotinib, an oral tyrosine kinase inhibitor that targets ALK, MET, and
ROS1 kinase, has emerged as an effective treatment for ROS1-rearranged NSCLC. In South …

ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This
retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine …

A 43-year-old Caucasian woman, lifelong nonsmoker, with a history of multiple sclerosis,
well controlled on natalizumab (alpha 4 integrin antagonist), presented with exertional chest …

Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases which accounts
for 80% of newly diagnosed lung cancers. In the previous decade, a new molecular subset …